Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06932263 · ClinicalTrials.gov registry record · Phase 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

A Phase 2 study of Asthma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
540
Enrollment target
20
Study locations

NCT06932263 is a Phase 2 study of Asthma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 540 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06932263, a Phase 2 study of Asthma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
540 participants
Enrollment target
20
Study locations

Study Summary

This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

Conditions Studied

Asthma

Interventions

  • DRUG Placebo
  • DRUG Tozorakimab

Study Locations (20)

Florida

  • Research Site - Cutler Bay
  • Research Site - Hialeah
  • Research Site - Hialeah
  • Research Site - Leesburg
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Orlando
  • Research Site - Palmetto Bay
  • Research Site - Tampa
  • Research Site - Winter Park

California

  • Research Site - Bakersfield
  • Research Site - Huntington Beach
  • Research Site - La Mesa
  • Research Site - Newport Beach
  • Research Site - San Jose

Delaware

  • Research Site - Wilmington

Idaho

  • Research Site - Boise

Indiana

  • Research Site - Indianapolis

Iowa

  • Research Site - West Des Moines

Kentucky

  • Research Site - Louisville

Trial Details

FieldValue
Enrollment Target 540 participants
Start Date 2025-03-26
Est. Completion 2028-03-16
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06932263

The ClinicalTrials.gov registry entry for NCT06932263 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (65% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06932263 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, California, Delaware.

Frequently Asked Questions

What is clinical trial NCT06932263 about?

NCT06932263 is a clinical study titled "Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids". This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.

What is the current status of trial NCT06932263?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 540 participants. The study started on 2025-03-26. Estimated completion is 2028-03-16.

What conditions does trial NCT06932263 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT06932263?

The interventions under investigation include: Placebo (DRUG), Tozorakimab (DRUG).

Who is sponsoring clinical trial NCT06932263?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06932263 being conducted?

This trial has 20 study locations across California, Delaware, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.